Diabetes mellitus tipo 1 inducida por interferón pegilado en 2 pacientes con hepatitis crónica c

Vera, J. Primo

doi:10.1016/s0210-5705(03)79089-x

Gastroenterología y Hepatología

2004

DOI: 10.1016/s0210-5705(03)79089-x

|View full text |Cite

Diabetes mellitus tipo 1 inducida por interferón pegilado en 2 pacientes con hepatitis crónica c

J. Primo Vera

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2010

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?

et al. 2007

View full text Add to dashboard Cite

We report the case of a 42-year-old woman with chronic hepatitis C (genotype 1), who in June 2004 started therapy with pegylated interferon alpha (PEG-IFNalpha) plus ribavirin. Two months later, she discontinued treatment because of polydipsia, polyuria and vomiting leading to a marked dehydration. Biochemical data showed type 1 diabetes mellitus with ketoacidosis, and insulin therapy was started. The patient, who before starting PEG-IFN alpha plus ribavirin therapy tested negative for glutamic acid decarboxylase antibodies (GADAb) and islet cell (ICAb) antibodies, became strongly positive for both autoimmune markers. This case confirms that patients with chronic hepatitis C who do not have baseline markers of pancreatic autoimmunity may develop severe ketoacidosis during treatment with PEG-IFNalpha, as well as with standard IFNalpha. In order to avoid this complication, as no guidelines are available and the pancreatic autoimmunity markers are not routinely analysed, we suggest frequent monitoring (e.g., every one to two weeks) of glycaemic values: e.g., every one to two weeks during the first 3 months (when this complication occurs most frequently) and monthly thereafter so as to identify diabetes at an early stage and before the onset of the appearance of severe ketoacidosis, which is life-threatening.

show abstract

A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?

et al. 2007

View full text Add to dashboard Cite

show abstract

Aparición de diabetes mellitus tipo 1 durante el tratamiento con interferón alfa: dos casos clínicos

Vinagre

Rigla

Torras

et al. 2010

Endocrinología y Nutrición

View full text Add to dashboard Cite

Onset of type 1 diabetes mellitus during peginterferon ??-2b plus ribavirin treatment for chronic hepatitis C

Cozzolongo

Betterle

Fabris

et al. 2006

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

A 61-year-old man was observed to develop type 1 diabetes mellitus following a 3-month treatment with recombinant alpha-2b peginterferon combined with ribavirin for chronic hepatitis C. Serum samples, collected before the start of therapy and 2 months after the diagnosis of diabetes mellitus, revealed islet-cell antibodies at a titer of 20 and 40 JDF-U, respectively, and glutamic acid decarboxylase autoantibodies at a value of 76.5 and 196 IU/ml, respectively. Antibodies to second islet autoantigen were persistently negative. HLA class II typing revealed the presence of DRB1*04/DRB1*14, DQA1*0303-0104 and DQB1*04-0503 alleles. Eight months after the onset of type 1 diabetes mellitus, the patient is still receiving 30 IU insulin daily; the liver function tests are normal and serum hepatitis C virus RNA is negative. These data confirm that, in patients with potential diabetes mellitus, the disease may become manifest as a side-effect during therapy with peginterferon-alpha plus ribavirin. The patient as a candidate for interferon treatment should therefore be investigated, in addition to thyroid autoimmunity, also for pancreatic autoantibodies before starting therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Diabetes mellitus tipo 1 inducida por interferón pegilado en 2 pacientes con hepatitis crónica c

Cited by 6 publications

References 10 publications

A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?

A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?

Aparición de diabetes mellitus tipo 1 durante el tratamiento con interferón alfa: dos casos clínicos

Onset of type 1 diabetes mellitus during peginterferon ??-2b plus ribavirin treatment for chronic hepatitis C

Contact Info

Product

Resources

About